Cellmid Provides Update on Midkine Patents for Europe and the US

Cellmid Limited (ASX: CDY) has reported that it received notice of allowance from the USPTO for the improved midkine antibody patent. Further, the European Patent Office has issued a ‘Decision to Grant’ for the improved midkine antibody patent.

  • The developments reflect major milestones in the midkine therapeutic program.
  • It adds significant commercial value and intellectual property to the portfolio.
  • It stems the intellectual property position of the company on the use of midkine therapeutic antibodies for treatments.
  • CDY’s midkine patent portfolio includes 67 patents and application in 12 patent families.

By 1:04 PM AEDT, CDY was trading at $0.225, up by 7.14 per cent from the previous close.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK